Comprehensive in vitro off-target screening services Safety-related drug failure is a major challenge for the pharmaceutical industry. Approximately 75% of adverse drug reactions (ADRs) are dose-dependent, related to a pharmacological action of the drug, and predictable. The interactions of drugs with off-target proteins have conventionally been viewed as undesirable ‘promiscuity’, responsible for unwanted side effects. …Read More >

Identify Potential Liability Issues in the Early Stages of Drug Discovery Drug-induced toxicity is a primary cause of failure for drug candidates during preclinical and clinical testing and a significant reason for approved drugs being removed from the market. Initial toxicity tests, which largely rely on animal studies, are essential during the nonclinical phase of …Read More >

A Platform Supporting HBV Drug Discovery A broad assay platform for the discovery of agents for the treatment of chronic HBV infection. Services for assay establishment and validation, compound screening and profiling, and support of preclinical studies and clinical trials. Drug screening using HBV producing cell lines HBV infectious assays Reporter assays Core protein expression …Read More >